Previous 10 | Next 10 |
home / stock / trgnf / trgnf news
Transgene (TRGNF) has received approval in France to proceed with a Phase I/IIa study of the novel oncolytic Vaccinia virus BT-001 developed with Invir.IO platform.This announcement follows approval received in December 2020 in Belgium. The first patient is expected to be enrolled in this tri...
Transgene (TRGNF): Q3 Operating revenue of €2M (-44% Y/Y)Cash and cash equivalents of €45.3M as of September 30, 2020.On October 20, 2020, company made an early repayment of the €10M loan granted by the European Investment Bank.Press Release For further details see...
Transgene ([[TRGNF]]), NEC Corp ([[NIPNF]]) and BostonGene have announced a strategic collaboration for two Phase 1 trials of TG4050, an individualized therapeutic vaccine for ovarian and head & neck cancers.TG4050 is based on Transgene’s proprietary myvac platform and NEC...
Transgene ( OTCPK:TRGNF ) raised $22.2M from the sale of 10.3M shares of its minority stake in Tasly BioPharmaceuticals to a Chinese investment fund, representing 38% of its total holding in Tasly BioPharmaceuticals. More news on: Transgene SA, Healthcare stocks news, , Read mor...
Ultra-thinly traded micro cap Transgene ( OTCPK:TRGNF +9.0% ) is up, albeit on turnover of only 2,100 shares, on the heels of a pooled analysis of data from a Phase 1b/2 clinical trial evaluating its HPV16-targeted therapeutic vaccine TG4001, combined with Pfizer ( PFE +3.7% ) a...
Transgene S.A. ( OTCPK:TRGNF ): Q1 Revenue of €3M (+50.0% Y/Y). More news on: Transgene SA, Earnings news and commentary, Tech stocks news, , Read more ...
Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more ...
Transgene S.A. ( OTCPK:TRGNF ): Q3 Revenue of €37.5M (+2243.8% Y/Y) More news on: TRANSGENE S.A., Earnings news and commentary, Tech stocks news, , Read more ...
French biotech Transgene ( OTCPK:TRGNF ) updates investors on its key clinical studies. More news on: TRANSGENE S.A., Healthcare stocks news, Read more ...
Transgene S.A. ( OTCPK:TRGNF ): 1H GAAP EPS of -€0.24. More news on: TRANSGENE S.A., Earnings news and commentary, Tech stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Transgene S.A. Company Name:
TRGNF Stock Symbol:
OTCMKTS Market:
Strasbourg, France, and Lund, Sweden, July 22, 2024, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stock...
Patient screening and enrollment initiated for the Phase II part of the international randomized Phase I/II trial with an overall sample size of approximately 80 patients. Last patient enrollment for Phase II part expected in Q4 2025. Strasbourg, France, June 3, 2024, 7:30 a....
TG4050: Exciting Phase I data presented at AACR 2024 demonstrating first signs of clinical benefit in adjuvant setting for head and neck cancer Phase II part of randomized trial to start in coming weeks New clinical data expected on TG4001, TG6050 and BT-001 in H2 2024 Financial vis...